Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.

Sponsor

The Institute of Molecular and Translational Medicine, Czech Republic (Other)

Overall Status

Recruiting

CT.gov ID

NCT06016569

Collaborator

Cancer Research Foundation CR (Other)

3,200

Enrollment

Locations

Arm

Anticipated Duration (Months)

1066.7

Patients Per Site

11.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer	Diagnostic Test: Exhaled breath condensate sampling Diagnostic Test: Blood sampling Procedure: LDCT Diagnostic Test: Vital signs Diagnostic Test: Spirometry	N/A

Detailed Description

The project aims to validate newly identified biomarkers of lung cancer in breath condensate for the diagnosis and triage of lung nodules (malignant versus benign), further set the mechanisms of the functioning of the lung cancer screening center, validate the quality indicators of LDCT screening for the Czech Republic and stratify the cohort of individuals so that optimized output of screening activities. Patients aged 55-74 years with a heavy smoking load (more than 20, preferably more than 30 pack/years) will be divided into risk groups according to biomarkers in exhaled air, clinical/anamnesis data and the degree of obstructive ventilation disorder according to spirometry and subsequently there will be effective stratification of the risk of lung carcinoma. The group with the highest risk of developing lung cancer will then be diagnosed with early lung cancer using ultra-low-dose computed tomography of the chest. This will lead to early diagnosis and subsequently to a reduction in the mortality rate of the monitored active group compared to the historical cohort. The primary outcome will be the validation of the multiplex protein signature in exhaled air, the effectiveness of the screening procedure to reduce lung cancer mortality and overall mortality in the group with FEV1 (forced expiratory volume at 1 second) pre-bronchodilation 60-75% with the entire group of examinees. The secondary outcome will then be the total time of diagnosis of a solitary pulmonary nodule in positively screened patients for whom only observation is not a sufficient procedure. Another secondary outcome will be the costs of screening procedures for individual groups and the percentage of success of the anti-smoking intervention for the enrolled individuals. The number of newly captured interstitial lung processes will also be evaluated. Patients will be evaluated for 5 years at annual visits or earlier based on their LDCT result.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

3200 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Screening

Official Title:

Prospective Validation Study of Early Cancer Biomarkers in Breath Condensate of Individuals With High-Risk of Lung Cancer Undergoing Low-Dose Computer Tomography Based Screening.

Actual Study Start Date :

Jun 1, 2023

Anticipated Primary Completion Date :

Dec 31, 2029

Anticipated Study Completion Date :

Dec 1, 2030

Arms and Interventions

Arm	Intervention/Treatment
Experimental: LDCT and collection of breath condensate and blood sample Each participant of the study will provide exhaled breath condensate sample and blood sample for further laboratory analyses. Each participant will have LDCT (low dose computer tomography) performed. A pulmonologist examines the patient for any concomitant diseases and performs spirometry. Vital signs will be measured.	Diagnostic Test: Exhaled breath condensate sampling Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed. Diagnostic Test: Blood sampling A venous blood sample will be taken for further biomarker analysis. Procedure: LDCT LDCT scan will be performed. Other Names: Low Dose Computer Tomography Diagnostic Test: Vital signs Blood pressure, weight, height, pulse, oxygen saturation will be measured. Diagnostic Test: Spirometry Spirometry will be performed.

Arm

Intervention/Treatment

Experimental: LDCT and collection of breath condensate and blood sample

Each participant of the study will provide exhaled breath condensate sample and blood sample for further laboratory analyses. Each participant will have LDCT (low dose computer tomography) performed. A pulmonologist examines the patient for any concomitant diseases and performs spirometry. Vital signs will be measured.

Diagnostic Test: Exhaled breath condensate sampling

Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.

Diagnostic Test: Blood sampling

A venous blood sample will be taken for further biomarker analysis.

Procedure: LDCT

LDCT scan will be performed.

Other Names:

Low Dose Computer Tomography

Diagnostic Test: Vital signs

Blood pressure, weight, height, pulse, oxygen saturation will be measured.

Diagnostic Test: Spirometry

Spirometry will be performed.

Outcome Measures

Primary Outcome Measures

Validation of the multiplex protein signature in exhaled air [5 years]
Validation of the multiplex protein signature in exhaled breath condensate based on the comparison with the LDCT.
Validation of the multiplex protein signature in exhaled breath for differential diagnostics of lung nodules [5 years]
Validation of the multiplex protein signature in exhaled breath for differential diagnostics of lung nodules
Assessment of the effectiveness of the screening program [5 years]
Assesment of the effectiveness of the screening procedure to reduce lung cancer mortality and overall mortality in the group with FEV1 (forced expiratory volume at 1 second) pre-bronchodilation 60-75% compared with the entire group of examinees.

Secondary Outcome Measures

Total time of diagnosis of the nodule [5 years]
The total time of diagnosis of a solitary pulmonary nodule in positively screened patients for whom only observation is not a sufficient procedure.
Comparison of costs of screening procedures [5 years]
Comparison of the costs of the screening procedures for exhaled breath condensate sample and LDCT procedure. This will be asssessed based on the individula patient data: total screening costs per patient from Healthcare registry in Czech Republic.
Assessment of success of the anti-smoking intervention [5 years]
Percentage success of the anti-smoking intervention in the examined probands.

Other Outcome Measures

Number of newly captured interstitial lung processes [5 years]
The number of newly captured interstitial lung processes will also be evaluated.

Eligibility Criteria

Criteria

Ages Eligible for Study:

55 Years to 74 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Consent to participate in a clinical trial.
A clients within an age of 55-74 years.
Current smoker or ex-smoker who has smoked at least 20 pack-years, provided that:
priority will be given to clients who have smoked at least 30 pack-years.
preference will be given to a former smoker who has not smoked for less than 15 years.

Exclusion Criteria:

Previous diagnosis of lung cancer.
Progressing malignant tumor on symptomatic treatment.
Advanced dementia
Chronic obstructive pulmonary disease or other inflammatory disease in the phase of acute exacerbation.